876376-75-9

Usage

Uses

Used in Pharmaceutical Industry:
(E)-1-(3-Chlorophenyl)-3-diMethylaMinopropenone is used as an intermediate in the synthesis of pharmaceutical drugs for its sedative and anxiolytic properties. It plays a crucial role in the development of medications aimed at treating anxiety disorders and insomnia, providing relief to patients suffering from these conditions.
Used in Organic Synthesis:
In the field of organic chemistry, (E)-1-(3-Chlorophenyl)-3-diMethylaMinopropenone serves as a valuable intermediate for the synthesis of various organic compounds. Its unique structure and reactivity make it a versatile building block for creating a wide range of chemical products, contributing to the advancement of the chemical industry.

Upstream product

• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 99-02-5 3'-Chloroacetophenone 
• 99-91-2 para-chloroacetophenone 

Relevant academic research and scientific papers

Rh(III)-Catalyzed Enaminone-Directed C-H Coupling with α-Diazo-α-phosphonoacetate for Reactivity Discovery: Fluoride-Mediated Dephosphonation for C-C Coupling Reactions

Rh(III)-catalyzed enaminone-directed C-H coupling with α-diazo-α-phosphonoacetate has been used for the identification of fluoride-mediated dephosphonation C-C coupling reactivity for the synthesis of 4-hydroxy-1-naphthoates. Intermolecular C-C coupling of α-phosphonoacetate and benzaldehyde for (E)-selective α,β-unsaturated ester synthesis has also been achieved.

Co(III)-Catalyzed Enaminone-Directed C-H Amidation for Quinolone Synthesis

We report herein the development of a Co(III)-catalyzed enaminone-directed C-H amidation method for synthetic access to quinolones, an important heterocyclic scaffold for diverse pharmaceutically active structures. The C-H coupling with dioxazolones and subsequent deacylation of an installed amide group allow consecutive C-N coupling generation of quinolones with wide-ranging compatible substituent patterns.

Protective effect of novel substituted nicotine hydrazide analogues against hypoxic brain injury in neonatal rats via inhibition of caspase

In hypoxic-ischemic injury of the brain of neonates, the level of caspase-3 was found to be aberrantly activated. Its overexpression leads to the alteration of cytoskeleton protein fodrin and loss of DNA repair enzyme which ultimately results in neurological impairment and disability. Concerning this, the present study was intended to develop novel nicotine hydrazide analogues as caspase inhibitors via efficient synthetic route. These compounds were subsequently tested for inhibitory activity against caspase-3 and -7 where they exhibit highly potent activity against caspase-3 revealing compound 5k as most potent inhibitor (IC50 = 19.4 ± 2.5 μM). In Western blot analysis, 5k considerably inhibits the overexpression of caspase-3. The aryl nicotinate of compound 5k, as indicated by molecular docking was found to engage His121 and critical enzyme thiols, i.e., Cys163 of caspase-3 for its potent activity. Moreover, histopathological examination of brain tissues and hippocampus neurons showed that compound 5k considerably improves the brain injury and exert neuroprotective effects in hypoxic-ischemic (HI). In brain homogenate, 5k significantly improves the activity of MDA, SOD, GSH-Px, CAT and T-AOC to exert its beneficial effect against oxidative stress induced by HI injury.

ORGANIC COMPOUNDS

Compounds of formula (I) in free or salt form, wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating a condition mediated by activation of the adenosine Alb recep

(Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines

This disclosure describes substituted 1,2,4-triazolo[1,5-a]pyrimidines and substituted 1,2,4-triazolo[4,3-a]pyrimidines which possess anxiolytic activity.